Edgewise Therapeutics, Inc.EWTXNASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank83
3Y CAGR+52.4%
Studio
Year-over-Year Change

Price-to-book ratio

3Y CAGR
+52.4%/yr
Annual compound
Percentile
P83
Within normal range
vs 3Y Ago
3.5x
Strong expansion
Streak
1 yr
Consecutive declineElevated
PeriodValueYoY Change
20254.89-9.0%
20245.37+145.7%
20232.19+58.2%
20221.38-49.9%
20212.76+106.2%
2020-44.18+49.6%
2019-87.61-